A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

Bristol-Myers Squibb

Overview

The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Chronic Hepatitis B

Interventions

EntecavirDRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

* Male and female subjects =/\> 16 years of age (or minimum age required in a given country) with history of HBeAg-positive chronic hepatitis B infection; * Incomplete response to current lamivudine therapy; * HBeAg-positive; * Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis D virus (HDV); * Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease.

Locations (39)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Local Investigator

Birmingham, Alabama, United States

Local Investigator

Tucson, Arizona, United States

Local Investigator

La Jolla, California, United States

Local Investigator

Los Angeles, California, United States

Local Investigator

Los Angeles, California, United States

Local Investigator

Orange, California, United States

Local Investigator

San Diego, California, United States

Local Investigator

San Francisco, California, United States

Local Investigator

Farmington, Connecticut, United States

Local Investigator

Miami, Florida, United States

...and 29 more locations